The r/MedSpa post asking about a newly launched buy-now-pay-later option at checkout is a small operational question with a large commercial answer. The practice already offers it; the owner wants to know how it behaves in a real checkout — what verification the customer goes through, and how much of that process is visible on the practice's side of a dual-screen terminal.
Those are the right questions to ask, and they are the second set of questions a practice should be asking. The first set is whether offering financing is a good idea at all, because payment terms change both the size of the treatment a client will book and the obligations the practice takes on.
What offering payments actually changes
The commercial case for financing in an aesthetic practice is that price sensitivity is often a matter of timing rather than willingness. A client who cannot comfortably pay for a series in one payment is not necessarily a client who does not want the series; she is a client with a cash-flow constraint in the month of the consultation. Offering to spread that payment converts a decision she would have deferred into one she can make in the room.
That effect is real, and it is why payment options tend to raise average transaction value in practices that offer them. It is also why the honest way to evaluate them is not by how much revenue they generate but by whether the financing produces treatment that would not otherwise have happened — because a client who would have paid in full regardless is now paying a financing cost for no additional benefit to herself, while the practice absorbs the lender's fee.
There is a second effect that gets less attention: financing changes the composition of the client base. Practices that advertise payment plans heavily tend to attract clients for whom price is the primary variable, which is the same client group that responds to discounts. That is not an argument against offering plans; it is an argument against marketing them as the headline. A payment option mentioned during a consultation about a treatment plan the client already wants behaves very differently from a banner that reads "affordable aesthetics."
The mechanics a practice needs to understand before switching it on
Several of these are worth settling in writing with whoever provides the financing, rather than discovering at a busy front desk.
Who the practice is actually being paid by. With most consumer financing, the practice is paid by the lender, not the client, and the client's obligation runs to the lender. That has consequences for reconciliation and for what happens when treatment is interrupted. If the client pays nothing to the practice, then a client who moves away mid-series has a debt relationship with a third party rather than an unfulfilled arrangement with the practice.
The cost of the facility. Consumer financing is not free to the merchant; the fee structure varies and should be compared against the incremental treatment it produces. A practice that cannot say what the facility costs per financed transaction cannot say whether it is working.
The refund and cancellation interface. This is where most of the operational difficulty sits. When a financed package is cancelled partway, the practice's refund, the lender's balance, and any fees sit in three places. The policy needs to be defined before the first financed client, not after the first dispute.
What the client sees versus what the practice sees. The owner's question about the dual screen is a good instinct. In practice, the client completes the application on the client-facing side, and the practice side typically sees the result of the decision rather than the underlying personal financial detail — which is the way it should be, because an application screen is not the place where a client expects her esthetician to be reading her credit information. The specific data each side sees is a question for the provider, and it is worth getting the answer in writing rather than assuming.
Disclosure. Consumer credit is regulated, and the disclosure obligations sit with the lender and appear on the client's application, not in the treatment room. The practice's responsibility is to not obscure the fact that the arrangement is a credit product with terms of its own, and to not suggest a plan is a discount or that treatment is being provided by the practice on instalments when it is not.
What it should never become
Two failure modes are worth naming because both are common.
The first is financing presented as a way to make treatment affordable when the honest problem is that the treatment plan is longer or more expensive than the client's situation supports. A nine-session programme sold on instalments to a client who will stop attending after three has not been sold; it has been transferred to a third party along with the complaint that follows. The clinical discipline of matching the plan to the client applies with more force, not less, when payment is easy.
The second is treating the financing as a conversational shortcut around the price. The consultation still needs to state the treatment price plainly and the client still needs to be choosing the plan on its merits. A practice that leads with monthly instalments has changed what the client is evaluating from the treatment to the payment — which is the same mistake as discounting, just with more steps and a third party involved.
How to decide whether to keep it on
Four measures answer the question over a quarter.
The first is the share of financed transactions that would not have happened otherwise. That is hard to know precisely, and it is worth asking the client directly at the point of sale, because the answer is usually clear to her.
The second is completion rate on financed series compared with series paid outright. If financed clients complete less often, the payment option is manufacturing commitments the practice then has to service through a third party.
The third is the facility's cost as a percentage of the incremental revenue it produced, measured against the practice's margin rather than against its revenue.
The fourth is the mix shift. If the financed share of bookings climbs steadily while average treatment value per client stays flat, the financing is not funding larger plans; it is funding the same plans with a fee attached.
The short version
Offering a payment plan is a reasonable tool for a practice whose consultations regularly produce plans that clients want and cannot pay for in one go. It works when the plan is sold first and the payment option second, when the practice knows what the facility costs and what it does to cancellations, and when the front desk has a written answer for what happens on a part-used series. It works badly when it is marketed as the reason to book, when it is used to avoid a conversation about price, or when it is used to sell programmes longer than the client's actual commitment — because in the second case the practice is not being paid by the person whose behaviour it needs to manage.